Academy of Finland
Funding decision
Name Piltonen, Terhi
Organisation OY
Project title
Anti-Müllerian hormone (AMH) –new player in the early onset pathogenesis of pregnancy complications and hormonal and metabolic derangements in women
Decision No. 321763
Decision date 22.05.2019
Funding period 01.09.2019 - 31.08.2023
Funding 549 946
WebFOCUS Report
Project description
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women, possibly stemming from prenatal androgen exposure. The affected women are at risk of metabolic and psychological disorders and pregnancy complications. Because of the adverse health impact on the women and high cost for society, new innovative and translational approaches are needed. In PCOS, serum levels of anti-Müllerian hormone (AMH) levels are elevated. Interestingly, high prenatal AMH exposure induces a PCOS-like phenotype in the female offspring of mice. Given this, the role of AMH in PCOS pathogenesis in humans warrants further studies. We aim to answer this question by utilizing endometria, sera, placentas, and umbilical cord blood samples from women with PCOS, and controls. Cell-culture and animal work will extend the work on early transmission of the phenotype. National registers and the Northern Finland Birth Cohort will bridge the research to a population level.